Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution - Archive ouverte HAL Access content directly
Journal Articles European Respiratory Journal Year : 2020

Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution

Abstract

Even for patients who are very stable while receiving i.v. epoprostenol over a long period of time, any transition to selexipag warrants careful long-term clinical and haemodynamic follow-up because worsening is likely to occur.
Fichier principal
Vignette du fichier
Yanaka_ERJ2020.pdf (384.48 Ko) Télécharger le fichier
Origin : Publication funded by an institution
Licence : CC BY - Attribution

Dates and versions

hal-04301533 , version 1 (23-11-2023)

Identifiers

Cite

Kenichi Yanaka, Alicia Guillien, Thibaud Soumagne, Justin Benet, Nicolas Piliero, et al.. Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution. European Respiratory Journal, 2020, 55 (6), pp.1902418. ⟨10.1183/13993003.02418-2019⟩. ⟨hal-04301533⟩
2 View
11 Download

Altmetric

Share

Gmail Facebook X LinkedIn More